Drug Discovery World

DECEMBER 20, 2022

As 2022 draws to a close, life sciences market analysts attempt to correctly predict what the next 12 months might bring to the drug discovery sector. In summary, 2023 could be a very exciting year for life sciences. DDW’s Diana Spencer summarises the key trends likely to impact the market in 2023. .

Drugs 52

Drugs Gene Editing Clinical Trials Clinical Trials 52

Roots Analysis

APRIL 4, 2023

In addition to the advances in processing power of computing machines and the development of smarter algorithms, big data is considered to be one of the key drivers of growth in this segment. Big data holds great promise in terms of its potential applications in the healthcare industry as mentioned below.

Big Data 52

Big Data Life Science Development Clinical Trials 52

ACRP blog

APRIL 5, 2023

AI is increasingly important in drug discovery and development as well as clinical trials, operations, pharmacovigilance, and many other areas.” This will also allow companies to utilize advanced computational models to find better treatments more quickly while also reducing costs associated with drug development.

Big Data 52

Big Data Clinical Trials Clinical Trials Life Science 52

pharmaphorum

NOVEMBER 30, 2020

In episode 26 the pharmaphorum podcast hears from David Solomon, a 30-year life sciences industry veteran who recently took up the position of CEO at the Paris-based biopharmaceutical company Pharnext.

Big Data 52

Big Data Life Science Development Drugs 52

pharmaphorum

FEBRUARY 1, 2022

David Clifton is professor of clinical machine learning in the Department of Engineering Science of the University of Oxford. His research focuses on the development of big data machine learning for tracking the health of complex systems. Mark holds a PhD in biomedicine, and an MSc in biostatistics.

Clinical Trials 104

Clinical Trials Clinical Trials Trials Engineer 104

The Pharma Data

JULY 12, 2021

online issue of Nature Communications, researchers at University of California San Diego School of Medicine describe a new approach that uses machine learning to hunt for disease targets and then predicts whether a drug is likely to receive FDA approval. the success rates in drug discovery?are biotech companies?have

Drugs 52

Drugs Gene Expression Big Data Gene 52

XTalks

OCTOBER 18, 2022

Global medical device company Nevro Corp has received US Food and Drug Administration (FDA) approval for the Senza HFX iQ spinal cord stimulation (SCS) system for the treatment of long-term or chronic pain. According to Nevro, the Senza HFX iQ is the first and only artificial intelligence (AI)-based SCS system that “learns from patients.”.

FDA Approval 98

FDA Approval Big Data Life Science Clinical Trials 98

pharmaphorum

OCTOBER 16, 2020

The repurposing of drugs is becoming more common, especially in the field of rare diseases. Now, as part of lifecycle management, pharmaceutical companies are looking more closely at drugs they have on their shelves. In the quest to repurpose a drug for a rare condition, there is a need to look at any and all available data.

Clinical Trials 105

Clinical Trials Clinical Trials Trials Life Science 105

XTalks

MAY 9, 2024

And in April 2024, we made a significant move to a 100 percent owned model with the acquisition of Profound Bio, a clinical-stage biotech company focused on developing innovative antibody-drug conjugate therapeutics for people with cancer. The next generation of drug discovery and development is an exciting prospect.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

Drug Discovery World

FEBRUARY 6, 2024

As AI-designed drugs start to enter large-scale clinical trials, DDW’s Diana Spencer investigates how new digital tools are reinventing and reshaping drug discovery for the future. Auransa, which harnesses available data to discover highly intractable diseases with poorly understood biology.

Marketing 69

Marketing Medicine Genome Genomics 69

Drug Discovery World

FEBRUARY 6, 2023

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care. He holds an MS degree in Statistics and a BS-equivalent in Bioengineering.

Big Data 52

Big Data RNA Bioinformatics Vaccination 52

pharmaphorum

MAY 25, 2021

One of the main reasons to use RWE is to counter a common criticism of the large phase 3 trials that for so long have been the ‘gold standard’ when developing drugs and gaining authorisations from regulators. BREATHE’s Jenni Quint said that the power is not just in information from wearables but the ability to link them with other data.

Big Data 135

Big Data Clinical Research Research Trials 135

XTalks

APRIL 5, 2021

Bioinformatics scientists also work in the field of computational biology, which combines science, mathematics, engineering and statistics to understand biological information. This job entails combining scientific information with computational information from databases to make sense of big data.

Bioinformatics 59

Bioinformatics Engineer Scientist Genome 59

Drug Discovery World

OCTOBER 12, 2022

DDW sits down with Mark Matson, Senior Solution Specialist for Sensor Cloud at Medidata, a Dassault Systèmes company, about the use of digital biomarkers in life sciences and how they can help advance our understanding of disease. . How do we define digital biomarkers? . About the author .

Clinical Trials 52

Clinical Trials Clinical Trials Trials Sales 52

pharmaphorum

SEPTEMBER 18, 2020

The profits from these products funded the development of new drugs, such as gastroesophageal treatment Losec and cardiovascular treatment Aptin. However, it withdrew its neuropharmacological drug, Zelmid, which was an SSRI, due to concerns over side effects only a year after it was introduced in 1982. Zeneca Group plc.

Pharma Companies 116

Pharma Companies Sales Vaccination Vaccine 116

Drug Discovery World

SEPTEMBER 6, 2022

There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. Among these include Zolgensma, Novartis’ gene therapy drug for spinal muscular atrophy (SMA), which made headlines in the UK for its £1.79 million price point per dose. Chris Nowers, CEO, ONK Therapeutics. . “

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

XTalks

AUGUST 2, 2023

Pfizer’s Top 5 Best-Selling Drugs of 2022: 1) Comirnaty Comirnaty is an mRNA-based vaccine indicated for the prevention of COVID-19. Comirnaty was first approved by the US Food and Drug Administration (FDA) in August 2021 for individuals over the age of 16. billion the drug generated in 2021. billion in 2022. billion, a 26.55

Sales 98

Sales Manufacturing FDA Approval Life Science 98

pharmaphorum

MARCH 16, 2021

By using AI we can extract all the information – including symptoms, signs and drug prescription outcomes throughout the patient journey.”. Savana’s platform harmonises data from different hospitals, countries, and languages into one single database, generating real world evidence. AI use in the pandemic.

Doctors 116

Doctors Doctor Life Science Clinical Research 116

Pharmaceutical Technology

JUNE 20, 2023

The current tech landscape is rapidly evolving, with advancements in areas such as big data and conversational platforms. Most of us have heard of ChatGPT and AI but where and how do they fit into the life sciences ecosystem? Neural networks learn to “translate” from language A to language B.

Life Science 130

Life Science Clinical Trials Clinical Trials Regulation 130

pharmaphorum

FEBRUARY 17, 2022

Led by researchers from the University of Oxford ‘s Big Data Institute, the study underscores the significance of analysing viruses continually over time. The VB variant. HIV first emerged in 1920 in the Democratic Republic of Congo, and, like other viruses, researchers monitored its evolution and anticipated it would mutate.

Genome 98

Genome Genomics Genetics Genotype 98

The Pharma Data

JANUARY 17, 2021

There has never been a time when rapid, low burden access to patient-level data, at scale, was more urgent. rows of data. Syntegra has also engaged with the Federal Drug Administration (FDA) to evaluate the role of synthetic data in regulatory decisions, for COVID-19 and beyond. .

Life Science 52

Life Science Engineer Big Data Scientist 52